This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| amiodarone | |
|---|---|
| Name | Amiodarone |
| Tradename | Cordarone, Pacerone, Nexterone |
| Routes | Oral, intravenous |
| Class | Antiarrhythmic (Class III) |
| Legal | Prescription only |
amiodarone is a potent antiarrhythmic medication used to treat a variety of life‑threatening cardiac rhythm disturbances. It is prescribed for ventricular tachycardia, ventricular fibrillation, and refractory atrial fibrillation and is administered in hospital and outpatient settings under specialist supervision. Developed in the mid‑20th century, it has complex pharmacology, a long half‑life, and a distinctive adverse effect profile that requires monitoring.
Amiodarone is indicated for sustained ventricular tachycardia and ventricular fibrillation refractory to other therapies and for rhythm control in persistent atrial fibrillation, often when cardioversion or catheter ablation such as Maze procedure is considered or contraindicated. It is used in advanced cardiac life support algorithms during cardiac arrest scenarios alongside interventions endorsed by American Heart Association and European Resuscitation Council. In patients with implanted devices such as pacemaker or implantable cardioverter-defibrillator, it is sometimes used to reduce arrhythmia burden or shocks, and in perioperative management during procedures like coronary artery bypass grafting and valve replacement surgery when arrhythmia risk is high.
Amiodarone primarily prolongs cardiac action potential duration by blocking potassium channels associated with repolarization, similar to Class III agents described in electrophysiology texts used by American College of Cardiology curricula. It also exhibits sodium channel blockade (Class I effects), beta‑adrenergic blocking properties (Class II effects), and calcium channel inhibition (Class IV effects), a multimodal profile noted in foundational studies involving researchers affiliated with Mayo Clinic and Johns Hopkins Hospital. The drug’s antiarrhythmic efficacy arises from suppression of abnormal automaticity and reentrant circuits previously characterized in electrophysiology research at institutions such as Massachusetts General Hospital and Cleveland Clinic.
Amiodarone is highly lipophilic with large volume of distribution, accumulating in adipose tissue and organs, a property documented in pharmacokinetic analyses from Food and Drug Administration submissions and academic reviews from University of Oxford researchers. Oral bioavailability is variable; hepatic metabolism by cytochrome P450 enzymes, especially CYP3A4 and CYP2C8, produces the active metabolite desethylamiodarone, a pathway studied at laboratories in National Institutes of Health and University of Pennsylvania. The terminal elimination half‑life ranges from weeks to months, necessitating loading regimens used in clinical trials at centres like Mount Sinai Hospital and Stanford Hospital. Intravenous formulations have different acute distribution and require monitoring per guidelines from European Society of Cardiology.
Amiodarone’s adverse effects are multisystemic and documented across observational cohorts from hospitals such as Brigham and Women's Hospital and registries maintained by American College of Cardiology. Pulmonary toxicity, including interstitial pneumonitis and fibrosis, can be severe and was characterized in case series reported by researchers at Royal Brompton Hospital and Mayo Clinic. Thyroid dysfunction — both hypothyroidism and hyperthyroidism — occurs due to iodine content and effects on thyroid hormone metabolism, phenomena investigated at Karolinska Institute and University of Tokyo. Hepatotoxicity, skin photosensitivity, corneal deposits, and neurologic symptoms such as peripheral neuropathy and ataxia have been described in publications from Cleveland Clinic and Johns Hopkins Hospital. Cardiac adverse events include bradycardia and rarely torsades de pointes, with monitoring recommendations from American Heart Association and European Medicines Agency.
Significant drug interactions arise from inhibition and induction of cytochrome P450 pathways; coadministration with agents metabolized by CYP3A4 such as simvastatin and antiarrhythmics like dronedarone or sotalol increases risk of toxicity and arrhythmia, as highlighted in drug interaction compendia from British National Formulary and Micromedex. Amiodarone potentiates anticoagulant effect of warfarin and requires dose adjustment and monitoring using international normalized ratio protocols promoted by World Health Organization blood safety guidelines. Concomitant use with drugs that prolong the QT interval, including certain macrolide antibiotics and fluoroquinolones, elevates torsades de pointes risk, noted in safety advisories from U.S. Food and Drug Administration and Health Canada.
Absolute contraindications include severe sinus node dysfunction or second‑ or third‑degree atrioventricular block without pacemaker support, based on consensus statements from European Heart Rhythm Association and American College of Cardiology. Caution is advised in patients with preexisting pulmonary disease, thyroid disease, hepatic impairment, or prolonged QT interval, with baseline and periodic evaluations recommended by societies such as American Thyroid Association and American College of Gastroenterology. Pregnancy and lactation considerations have been discussed in guidelines from Royal College of Obstetricians and Gynaecologists and teratology research groups at Centers for Disease Control and Prevention.
Amiodarone was first synthesized in the late 1950s and developed for antianginal use before its antiarrhythmic properties were recognized in clinical observations at European centres including Hôpital Broussais and pharmacology groups associated with Université Paris Descartes. Clinical adoption accelerated after randomized and observational studies in the 1970s and 1980s from institutions such as Harvard Medical School and University of California, San Francisco demonstrated efficacy in refractory ventricular arrhythmias. Regulatory approvals and post‑marketing surveillance by agencies including U.S. Food and Drug Administration and European Medicines Agency shaped modern labeling, while ongoing research at academic centres like Imperial College London and Johns Hopkins University continues to refine indications, dosing strategies, and safety monitoring.
Category:Antiarrhythmic agents